Answers are grounded in this paper and cite their sources.
Visceral leishmaniasis (VL), a disease associated with poverty, is endemic in the Indian subcontinent and Africa (where it is caused by the protozoan parasite Leishmania donovani, and in Latin America and the Mediterranean region (where it is caused by L. infantum).In all regions, it is transmitted by the female sand fly vector.Although there has been a substantial decline in the number of reported cases in recent years, VL continues to affect many tropical and subtropical countries, despite international, national, and local efforts towards its control and elimination over the past several decades.In 2005, a target for the elimination of VL, defined as reducing incidence to a level where it would no longer be of public health importance, i.e., <1 per 10,000 inhabitants per year at each health intervention unit from India, Nepal, and Bangladesh, was set for 2015.This target date was missed, as was a second target date of 2017.WHO has recently reset the target date to 2020 for the elimination of this disease from the Indian subcontinent (ISC).To review the progress and prospects made towards elimination, an International Conference on Innovations for the Elimination and Control of Visceral Leishmaniasis (IEC-VL'18) was held in New Delhi, India from 28-30 November 2018.Discussions and debates throughout the conference were aimed to provide a focus for stakeholders and decision makers to frame further control measures and policies and to define needed research and tools.Thus, innovations that would be key during the "last mile" towards reaching the elimination targets needed emphasis.A focus on the challenges due to loss of immunity, parasite and human population heterogeneities, noncompliance to control measures, and reasons for outbreaks and resurgence of the disease is needed.Significant advances in the discovery and development of new drugs, diagnostics, vaccines, and vector control measures that offer opportunities for future interventions need to be highlighted. Progress made during the elimination programFrom 2005, the year of regional elimination initiative in Nepal, there has been decline in the kala-azar (VL) cases from 2,220/10,000 in 2003 to only 254 in 2017.However, in recent years, the region has witnessed an increase in the number of cases coming from previously nonendemic hilly regions [1,2].The cases of untreated post-kala-azar dermal leishmaniasis (PKDL) patients, a sequela of VL after treatment, has also increased; this potential reservoir of Leishmania creates concerns over the possibility of future epidemics [2].Recent data, based upon sand fly feeding studies, suggests that disease transmission from PKDL cases is likely, with
No takes yet. Share an insight, caveat, or question.
Selvapandiyan et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: